Patents Assigned to SpliSense Ltd.
  • MUC5AC-TARGETED ANTISENSE OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING MUCIN EXPRESSION
    Publication number: 20250297247
    Abstract: The present invention provides specific synthetic oligonucleotides, as well as vectors, cells, and pharmaceutical compositions comprising the oligonucleotides, and their use in methods of treating, suppressing, inhibiting, ameliorating, or slowing progression of a lung disease or disorder, such as chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), and non-cystic fibrosis bronchiectasis (NCFB).
    Type: Application
    Filed: December 8, 2022
    Publication date: September 25, 2025
    Applicant: SpliSense Ltd.
    Inventors: Gili HART, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR, Chava STAMPFER
  • Restoration of the CFTR function by splicing modulation
    Patent number: 12351803
    Abstract: The present invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, including compositions comprising the oligonucleotides, and uses thereof, such as for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849+10Kb C-to-T, optionally in combination with additional CF therapeutics.
    Type: Grant
    Filed: July 7, 2024
    Date of Patent: July 8, 2025
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., SpliSense Ltd.
    Inventors: Bat Sheva Kerem, Efrat Ozeri-Galai, Yifat Oren, Ofra Barchad-Avitzur
  • MUC5B-TARGETED ANTISENSE OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING MUCIN EXPRESSION
    Publication number: 20240409930
    Abstract: The present invention provides specific synthetic oligonucleotides, as well as vectors, cells, and pharmaceutical compositions comprising the oligonucleotides, and their use in methods of treating, suppressing, inhibiting, ameliorating, or slowing progression of a lung disease or disorder, such as chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), and non-cystic fibrosis bronchiectasis (NCFB).
    Type: Application
    Filed: May 21, 2024
    Publication date: December 12, 2024
    Applicant: SpliSense Ltd.
    Inventors: Gili HART, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR, Chava STAMPFER
  • RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION
    Publication number: 20240352461
    Abstract: The present invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, including compositions comprising the oligonucleotides, and uses thereof, such as for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849+10 Kb C-to-T, optionally in combination with additional CF therapeutics.
    Type: Application
    Filed: July 7, 2024
    Publication date: October 24, 2024
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., SpliSense Ltd.
    Inventors: Bat Sheva KEREM, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR
  • COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20230142669
    Abstract: The present invention is directed to a method for inducing skipping of exon 24 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Further, treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 24 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator.
    Type: Application
    Filed: March 25, 2021
    Publication date: May 11, 2023
    Applicant: SpliSense Ltd.
    Inventors: Yifat OREN, Ofra BARCHAD-AVITZUR, Efrat OZERI-GALAI
  • COMBINATION TREATMENTS FOR CYSTIC FIBROSIS CHARACTERIZED BY A 3849 + 10KB C-TO-T CFTR MUTATION
    Publication number: 20220220486
    Abstract: The present invention provides methods for treating Cystic Fibrosis (CF) and methods for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849+10 Kb C-to-T comprising the step of administering a pharmaceutical composition comprising synthetic oligonucleotides complementary to a region of the CFTR comprising the 3849+10 Kb C-to-T mutation oligonucleotides and a composition comprising one or more CFTR modifiers.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 14, 2022
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, SPLISENSE LTD.
    Inventors: Bat Sheva KEREM, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR
  • RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION
    Publication number: 20220213479
    Abstract: The present invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, including compositions comprising the oligonucleotides, and uses thereof, such as for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849 +10 Kb C-to-T, optionally in combination with additional CF therapeutics.
    Type: Application
    Filed: May 5, 2020
    Publication date: July 7, 2022
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, SpliSense Ltd.
    Inventors: Bat Sheva KEREM, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR
  • COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20220064647
    Abstract: The present invention is directed to a method for treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 23, exon 24, or both, of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator, and a method of producing thereof.
    Type: Application
    Filed: March 29, 2020
    Publication date: March 3, 2022
    Applicant: SpliSense Ltd.
    Inventors: Yifat OREN, Ofra BARCHAD-AVITZUR, Efrat OZERI-GALAI
  • COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20220040219
    Abstract: The present invention is directed to a method for treating cystic fibrosis (CF) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 23 of the cystic fibrosis transmembrane conductance regulator (CFTR) pre-mRNA. Also provided are a composition and a kit comprising the splicing modulator, and a method of producing thereof.
    Type: Application
    Filed: March 29, 2020
    Publication date: February 10, 2022
    Applicants: SpliSense Ltd., THE HOSPITAL FOR SICK CHILDREN
    Inventors: Christine BEAR, Onofrio LASELVA, Steven MOLINSKI, Yifat OREN, Ofra AVITZUR-BARCHAD, Efrat OZERI-GALAI